Mike Sicilia is certainly not the first big technology boss to rediscover his passion for coding, but in healthcare, his enthusiasm couldn’t come at a more critical moment.

On a flying visit to London as part of Oracle’s AI World Tour, Sicilia, co-chief executive of the $420 billion software giant, told The Times he was having a “ton of fun” getting back into programming for the first time in years. The catalyst? Advances in generative AI that allow anyone to describe in plain English what they want a computer to build. “Stunningly impressive,” is his verdict, though he’s quick to note none of his personal coding experiments have made it into Oracle’s production systems. Yet.

For health systems, hospital networks, and the life sciences sector, that word, yet, carries enormous weight.

A Digital Backbone for Healthcare

Oracle is, in many ways, the world’s most powerful digital filing cabinet. It provides the heavy-duty databases, cloud computing infrastructure, and enterprise applications that major global organisations, including some of the largest health systems on earth, depend on to function. If Epic is the face of hospital IT, Oracle is often the foundation beneath it.

That position deepened dramatically in 2022 when Oracle acquired Cerner, one of the world’s largest electronic health record (EHR) providers, for $28 billion. Overnight, Oracle became one of the most consequential players in healthcare technology, responsible for the clinical and administrative records of tens of millions of patients.

Sicilia’s day job, then, is not just running a technology business. It is running infrastructure that clinicians rely on to make life-or-death decisions.

AI Agents in the Clinic

Just six months into his role as co-CEO, Sicilia already has his own AI coding agent. He can flag a suspected error and the agent responds: “Yes, you’re right. Let me go fix this.” Tasks that once took months, he says, now take hours.

Translate that into a healthcare context and the implications are profound. Oracle has been deploying AI agents directly into clinical workflows, helping reduce the documentation burden that has driven epidemic levels of physician burnout. Ambient AI that listens to patient consultations and auto-populates EHR notes. Intelligent triage tools that surface deteriorating patients before a crisis unfolds. Automated prior authorisation systems that slash the administrative friction consuming clinical staff time.

The promise is a shift from reactive to predictive care, and Oracle, as custodian of some of the richest longitudinal patient datasets in existence, is positioned at the centre of it.

The Workforce Question

Sicilia’s own rekindled enthusiasm for coding quietly illuminates one of healthcare’s most pressing anxieties: what happens to the workforce? Oracle recently announced it is setting aside an additional $500 million this financial year to cover restructuring costs, a total of $2.1 billion, with reports suggesting up to 30,000 jobs could go across the company.

“If there are situations where AI makes certain roles redundant, then we owe it to shareholders to make sure that we’re running the company as efficiently as we can,” Sicilia said.

Healthcare leaders will recognise the tension immediately. The same logic applies when AI can read a radiology scan, draft a clinical letter, or code a diagnosis. The question is not whether roles will change, they will, but whether health systems are investing in the retraining and transition support that staff deserve. Unlike the tech sector, healthcare cannot simply restructure its way to efficiency. Every displaced role touches patient care.

The Infrastructure Gamble and What It Means for Health Data Sovereignty

Oracle is part of the $500 billion US Stargate AI infrastructure programme alongside SoftBank and OpenAI. It has raised $30 billion in debt financing to fund a vast data centre buildout. OpenAI alone has signed a reported $300 billion computing deal with Oracle, and could account for more than a third of Oracle’s revenues by 2028.

For healthcare, this matters beyond the financial pages. Oracle’s data centres host some of the most sensitive personal information that exists: patient records, genomic data, clinical trial results. The company has pledged $5 billion in UK investment over five years and counts the British government among its customers.

Sicilia is sanguine about concerns that US-controlled infrastructure in Europe could be politically vulnerable, arguing that allied nations will continue to stand together. Health system CIOs and NHS procurement teams may want more than reassurance. Data residency, sovereignty, and the right to audit are not abstract compliance questions in healthcare; they are the foundation of patient trust.

Sicilia does offer one notable comfort: Oracle’s data centres are, he says, “fungible,” meaning their use can switch rapidly regardless of the technology inside. For health systems worried about long-term vendor lock-in, that flexibility is worth holding him to.

The Longer Game: Cancer, Longevity, and the AI Dividend

Despite inevitable turbulence, shareholder lawsuits, volatile stock performance, and the looming question of whether Oracle’s fortunes are too tightly bound to OpenAI’s success, Sicilia remains a committed techno-optimist.

“Can we increase the longevity of human lives? Can we make real progress against cancer?” he asks. “My hope is that this will lead to an even greater level of entrepreneurship, going forward.”

These are not rhetorical flourishes in a healthcare context. Oracle’s clinical data infrastructure, combined with AI’s capacity to identify patterns across millions of patient records, represents a genuine opportunity to accelerate drug discovery, personalise treatment, and close the long-standing gaps in diagnostic equity that have plagued healthcare systems worldwide.

At almost 50 years old, Oracle is a middle-aged company determined to stay relevant. Its bet is that AI is not a threat to its business model but the amplifier of it, particularly in an industry like healthcare, where the data is vast, the stakes are existential, and the need for trustworthy infrastructure has never been greater.

Whether Oracle can deliver on that promise, for patients, not just shareholders, is the question health system leaders should be asking.